

CORRECTION

Correction: Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in *MET*-Amplified Esophagogastric Cancer

In this article (Cancer Discov 2015;5:1271–81), which was published in the December 2015 issue of *Cancer Discovery* (1), the author list is incomplete as it appears in print. The complete author list, along with corresponding affiliations, is provided below.

Eunice L. Kwak^{1,2}, Leanne G. Ahronian^{1,2}, Giulia Siravegna^{3,4}, Benedetta Mussolin^{3,4}, Darrell R. Borger⁵, Jason T. Godfrey^{1,2}, Nicholas A. Jessop⁵, Jeffrey W. Clark^{1,2}, Lawrence S. Blazzkowsky^{1,2}, David P. Ryan^{1,2}, Jochen K. Lennerz⁵, A. John Iafrate⁵, Alberto Bardelli^{3,4}, Theodore S. Hong^{1,6}, and Ryan B. Corcoran^{1,2}

¹Massachusetts General Hospital Cancer Center, Boston, Massachusetts. ²Department of Medicine, Harvard Medical School, Boston, Massachusetts. ³Department of Oncology, University of Torino, Torino, Italy. ⁴Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Torino, Italy. ⁵Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. ⁶Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Accordingly, the authors' contributions section as it appears in print is incomplete. The now-included authors are credited with those contributions listed alongside their names below.

Darrell R. Borger: Conception and design; Development of methodology; Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.); Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis); Writing, review, and/or revision of the manuscript; Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases).

Nicholas A. Jessop: Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.); Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases).

The disclosure of potential conflicts of interest statement as it appears in print remains unchanged.

The online version of the article has been changed to reflect the content of this correction. The authors regret these omissions.

REFERENCE

1. Kwak EL, Ahronian LG, Siravegna G, Mussolin B, Borger DR, Godfrey JT, et al. Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in *MET*-amplified esophagogastric cancer. *Cancer Discov* 2015;5:1271–81.

Published OnlineFirst November 21, 2016.

doi: 10.1158/2159-8290.CD-16-1271

©2016 American Association for Cancer Research.

CANCER DISCOVERY

Correction: Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in *MET*-Amplified Esophagogastric Cancer

Cancer Discov 2016;6:1402. Published OnlineFirst November 21, 2016.

Updated version Access the most recent version of this article at:
doi:[10.1158/2159-8290.CD-16-1271](https://doi.org/10.1158/2159-8290.CD-16-1271)

Cited articles This article cites 1 articles, 1 of which you can access for free at:
<http://cancerdiscovery.aacrjournals.org/content/6/12/1402.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerdiscovery.aacrjournals.org/content/6/12/1402>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.